ATR02
Ro(SSA)
Native - Animal Derived
Ro RNP | SSA antigen | Ro60 antigen | Sjögren's syndrome antigen A
Uniprot IDs: | |
mRNA RefSeq: | |
Protein RefSeq: |
Product Information
Autoantibodies to the Ro(SSA) antigen are one of the most frequent serological markers of autoimmunity in rheumatic diseases. They are present in the serum of 70-100% of patients with Sjögren’s syndrome (SS), 40-90% of patients with systemic lupus erythematosus (SLE), and 3-15% of patients with rheumatoid arthritis (RA)1.
Ro(SSA) autoantibodies have also been reported to be present in subacute cutaneous lupus erythematosus, neonatal lupus syndrome, polymyositis, dermatomyositis, systemic sclerosis and primary biliary cirrhosis1. The incidence of anti-Ro(SSA) antibodies in the population of normal women of reproductive age is in the order of 1%2.
The presence of anti-La(SSB) autoantibodies usually coincides with the presence of anti-Ro(SSA)1. There is also a second anti-Ro autoantibody system, against a 52kDa antigen (Ro52). This is an immunologically independent autoimmune system, though anti-Ro52 antibodies can be present along with anti-Ro(SSA) antibodies in systemic autoimmune diseases1.
Ro(SSA) antibodies target a 60 kDa protein (Ro60) that is associated with small non-coding RNAs molecules known as hY-RNAs. It has been reported that the Ro60 protein may act as part of a quality checking system for misfolded or defective RNA1.
The Ro60 protein represents the primary component of AROTEC’s Ro(SSA) antigen. The antigen typically exhibits a 260nm/280nm absorbance ratio of >1.3, indicating that the hY-RNA component is present. The binding of autoantibodies to Ro60 is mostly conformational. Many Ro(SSA) antibodies lose their binding activity when presented with a denatured protein1.
The known human Ro60 antigen amino acid sequences have a very high degree of homology to the bovine sequence (>90%), indicating that Ro(SSA) is highly conserved between mammalian species. The use of bovine antigen for the detection of anti-Ro(SSA) antibodies has been described elsewhere3-5.
Clinical Indications
Sjögren’s Syndrome
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Neonatal Lupus Syndrome
Certificate of Analysis
Please log in to view certificates of analysis for this item
References
- Yoshimi, et al. (2012) Clin. Dev. Immunol. 2012, 2012:606195
- Calmes, & Bartholomew, B.A. (1985) J. Clin. Pathol. 38, 73
- Gaither, K. et al. (1987) ) J. Clin. Invest. 79, 841
- Yamagata, et al. (1984) J. Clin. Invest. 74, 625
- Yoshida, & Reichlin, M. (1990) J. Immunol. Methods 131, 113